China and the US adopted different strategies for the COVID-19 pandemic. Companies in these two countries will face different legacy issues, but a cautious outlook for 2022 is probably warranted.
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.